News · 26 weeks470%
2026-04-192026-10-11
Mix2990d
- Other15(52%)
- SEC Filings14(48%)
Latest news
25 items- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance TechnologiesTEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies. Agentic AI refers to artificial
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum ArchitectureTEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. ("CliniQuantum"), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated ("GPU") quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit ("CPU")
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsThe U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. ("Clear
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK StrategiesThis strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration ("FDA") Orphan Drug Designation covering SCI-110, its drug candid
- SECSEC Form EFFECT filed by SciSparc Ltd.EFFECT - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical TrialTEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s innovative SCI-210 treatment for symptoms associated with autism spectrum disorder ("ASD"). The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 chil
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory BoardThe addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market TEL AVIV, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced the addition of Prof. Carmel Domshlak, an internationally recognized artificial intelligence ("AI") expert and professor at the Technion – Israel Institute of Technology ("Technion"), to the Company’s newly established Scientific Advisory Board for AI and Cybersecurity, effective September 1, 2026. Prof. Domshlak’s addition represents a further step in SciSparc’s efforts to build a strong scient
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic InnovationU.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has advanced wi
- SECAmendment: SEC Form F-3/A filed by SciSparc Ltd.F-3/A - SciSparc Ltd. (0001611746) (Filer)
- SECAmendment: SEC Form 20-F/A filed by SciSparc Ltd.20-F/A - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 MillionSciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financing TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million. SciSparc participated in the financing with a C$2.7 million investment, representing 50% of the total gross proceeds r
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic CombinationTEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols." The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette SyndromeTEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced the initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome ("TS") in adults. The trial is now progressing at the Yale Child Study Center,
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
SPRC FAQ
5 questionsWhat does SciSparc Ltd. do?
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health...Where does SPRC stock trade?
SciSparc Ltd. (SPRC) is listed on NASDAQ.What sector and industry is SPRC in?
SciSparc Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SPRC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRC side-by-side with any of them on Quantisnow.How can I track SPRC on Quantisnow?
Quantisnow aggregates SciSparc Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRC to receive live email and push alerts on every new disclosure.